[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$flFBex_i2nhfK_OPP8aspB0P4Zxk6Rr2an4u_cEh9jMA":8,"$fRYS33STL-Z1Ardzi275W1LLzzqI6R4YOUoTCfHU11HI":55,"$f0JoBZjej41Gl1931lRxBTv9DN1tXcM6X-u1uFKUlRmw":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},75888,867263,[],"https://ystcdn.venuertc.com/medical/ystApp/0YbWrtsGnIVSTzEaDbtlD7CaJRSwuqG9.png","李会敏","临清市人民医院","老年病内科","住院医师",384,0,"肺腺癌四期老年患者的主要用药方案与安全细节解析","","https://ystcdn.venuertc.com/venue/AI/71482d38-7bd7-4907-a9b2-b303d587481a.jpg","\u003Cdiv class=\"practical-drug-guide\">\n  \u003C!-- 标题 -->\n  \u003Ch1 id=\"material_title\" class=\"practical-drug-guide__main-title\">\n    肺腺癌四期老年患者的主要用药方案与安全细节解析\n  \u003C/h1>\n  \n  \u003C!-- 导语 -->\n  \u003Cdiv class=\"practical-drug-guide__lead\">\n    \u003Cp>\n      在四期肺腺癌老年患者的治疗中，药物方案的细节直接影响用药效果和安全性。本文重点讲解抗肿瘤药、靶向药以及支持用药的剂型、用法、相互作用、不良反应、特殊人群调整以及储存方法等7类关键细节。无论是患者本身还是照护家人，了解正确用药流程，能更好地规避风险、提升生活质量。接下来，带你系统梳理这些最实用的药物知识。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003C!-- 正文1：多样剂型及服用技巧 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg1\">\n      \u003Ch2>01 各类抗肿瘤药的剂型及服用技巧 🎯\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>化疗药物（如顺铂、卡铂、培美曲塞）\u003C/strong>：多为注射剂型，静脉滴注为主。静脉给药需由专业医护操作，不能自行注射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗\u003C/strong>：为注射用单抗类药物，只能静脉注射，须专业人员配制使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>靶向药物（如达拉菲尼/曲美替尼等BRAF抑制剂）\u003C/strong>：以片剂或胶囊为常见剂型，须整片/粒吞服，不能嚼碎或压碎。\n          \u003Cbr>正确做法：用约200ml清水送服，避免与热饮或果汁等一同服用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>辅助药物（如止吐药、护肝药等）\u003C/strong>：常见片剂、胶囊、注射剂类型。针对咽下困难的患者，可选用易吞服剂型如分散片或药水。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        需要注意：部分药物说明“空腹”或“餐后”服用，务必按说明或医师指示执行，不随意更改。举例来说，部分BRAF抑制剂强调空腹服用，以免影响吸收。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文2：服用时间和方法要点 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg2\">\n      \u003Ch2>02 抗肿瘤药的服用时间与方法⏰\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>多周期治疗规律：\u003C/strong> 化疗及贝伐珠单抗等注射药物遵循“周期制”，每周期通常间隔2-3周。\n          \u003Cbr>接受注射药物后必须观察30分钟以上，防范即刻过敏反应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>口服靶向药或辅助药物：\u003C/strong>每日定时服用，宜固定时间，如早八晚八。\n          \u003Cbr>建议使用药盒、闹钟等工具避免忘服或重复。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>漏服弥补方法：\u003C/strong> 常见靶向药如达拉菲尼、曲美替尼漏服在6小时内可补服，超过时间则直接跳过，不叠加剂量（详见说明书）。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：用药期间按规定时间服药，避免因漏服导致耐药风险。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文3：药品作用机制简明解读 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg3\">\n      \u003Ch2>03 主要药物的作用原理速览🔬\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>化疗药（如顺铂、卡铂）\u003C/strong>：通过干扰DNA合成和分裂，阻断肿瘤细胞增殖。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>培美曲塞：\u003C/strong> 抑制DNA合成相关酶，阻止肿瘤细胞复制。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong> 靶向VEGF，抑制肿瘤新生血管生长，限制养分供应。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>靶向药（如达拉菲尼、曲美替尼）\u003C/strong>：专门抑制BRAF等异常蛋白的信号通路，减少肿瘤细胞异常生长。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        上述药物机制有各自特点，因此不能互换使用，应由医生为您量身选择方案。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文4：特殊人群用药调整标准 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg4\">\n      \u003Ch2>04 老年人及慢病患者的用药调整策略 👴🏼👵🏻\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>剂量个体化：\u003C/strong> 对于75岁及以上、肝肾功能减退、营养状态不佳者，抗肿瘤药通常起始剂量下调。\n          \u003Cbr>例如含铂方案化疗，老年患者起始剂量约为常规剂量的70%-80%。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>肝肾损害调整：\u003C/strong> 慢性乙型肝炎患者须严控抗肿瘤药剂量，定期监测肝肾功能。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>合并高血压、糖尿病：\u003C/strong> 使用贝伐珠单抗需先控制血压至140/90mmHg以下，糖尿病患者须优化血糖，预防并发症影响药物代谢。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>联合用药考虑：\u003C/strong> 老年患者常多病共存，应梳理所有药品清单，避免药物重叠和不当联合。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        特别提醒：服药过程中，任何剂量调整须由医生操作，不得自行加减量。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文5：典型药物相互作用全解 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg5\">\n      \u003Ch2>05 抗肿瘤药物的相互作用 ⚠️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>化疗药与护肝药\u003C/strong>：部分肝药可延迟化疗药清除，增加毒性，具体如还原型谷胱甘肽应与化疗药分开时段使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>达拉菲尼（口服）\u003C/strong>与止吐、降糖药：部分药品会通过肝酶系统影响达拉菲尼的代谢浓度，需告知医生所有正在使用的药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗与抗高血压药\u003C/strong>：部分降压药可能增强贝伐珠单抗诱发的蛋白尿风险。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>抗凝药与贝伐珠单抗\u003C/strong>：联合使用易致出血，不推荐长期合用，除非医生判断有特殊需求。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        正确做法：所有新加药物，提前报备医生，由专业医师评估药物相互作用，减少发生率。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文6：不良反应监控与处理要点 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg6\">\n      \u003Ch2>06 常见不良反应及处理方案 🚨\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>化疗药：\u003C/strong> 可能出现白细胞减少、恶心、脱发等，说明书提示白细胞减少发生率可达80%。出现严重疲倦、高热须及时复诊，勿自行停药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong> 约20%-30%患者出现高血压、蛋白尿。首次发现血压持续升高应及时联系医生评估是否暂停用药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>BRAF抑制剂：\u003C/strong> 皮疹、发热、肌痛等较为常见。发热时服用对乙酰氨基酚并充分补液，多数可缓解。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>辅助药：\u003C/strong> 某些止吐药可导致口干、头晕等副作用，应关注自身变化，必要时调整种类。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        处理方法：定期血液检查、关注身体变化，异常时应及时就医，切勿私自更换药物。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 正文7：药品储存条件与过期药处理 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg7\">\n      \u003Ch2>07 药品储存与过期药物管理 📦\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>口服药：\u003C/strong> 储存在干燥、避光、室温(15-25℃)条件下。分装药盒须3天用完，避免受潮变色。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>注射剂：\u003C/strong> 封闭包装，避光冷藏(2-8℃)，不得冷冻。开封后24小时内用完。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过期药品：\u003C/strong> 按说明书或药店回收渠道回收，不要随意丢弃生活垃圾。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        特别提醒：按包装储存是降低药效损失、防止细菌污染的关键手段。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 用药实际案例展示 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg8\">\n      \u003Ch2>用药案例集锦 💡\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          一位80岁男性患者在贝伐珠单抗联合化疗期间，密切监测血压和肾功能，预防了蛋白尿和严重高血压。\n        \u003C/li>\n        \u003Cli>\n          临床上使用达拉菲尼（针对BRAF突变）时，定期检查肝功能，及时识别可逆性转氨酶升高情况。\n        \u003C/li>\n        \u003Cli>\n          患者在抗肿瘤注射药物治疗前，详细告知正在用的降压药、抗糖药，医生调整治疗方案后避免了药物间严重相互作用。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 关键数据及安全用药简明笔记 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg9\">\n      \u003Ch2>关键数据 & 用药安全小贴士 📊\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content\">\n      \u003Cul>\n        \u003Cli>\n          临床研究显示：顺铂联合贝伐珠单抗的客观缓解率在30%-40%之间 (Reck et al., 2009)。\n        \u003C/li>\n        \u003Cli>\n          BRAF抑制剂皮肤不良反应发生率可达15%-30% (Hauschild et al., 2012)。\n        \u003C/li>\n        \u003Cli>\n          贝伐珠单抗诱发蛋白尿发生率约18%，严重高血压发生约8% (Hurwitz et al., 2004)。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        💡药品安全关键：剂型正确、时间准确、监测并报告不良反应。高龄和多病合并用药尤其要遵医嘱，切勿擅自调整任何药品！\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n  \n  \u003C!-- 结语：安全用药再强调 -->\n  \u003Cdiv class=\"practical-drug-guide__conclusion\">\n    \u003Cp>\n      老年患者在肺腺癌四期治疗中，安全用药只有一条底线——正规剂型、规范时间、主动监测和报备。在治疗路上，记住这些药品要点，既能帮助更好抗击病魔，还能少走弯路、规避风险。任何疑问和新用药前，务必与专业医生沟通，再做决定。\n    \u003C/p>\n  \u003C/div>\n  \n  \u003C!-- 文献引用 -->\n  \u003Csection class=\"practical-drug-guide__section\">\n    \u003Cdiv class=\"practical-drug-guide__section-header practical-drug-guide__bg10\">\n      \u003Ch2>引用文献\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"practical-drug-guide__section-content practical-drug-guide__refs\">\n      \u003Col>\n        \u003Cli>\n          Reck M, et al. \"Avastin (bevacizumab) in combination with cisplatin/gemcitabine or carboplatin/paclitaxel in previously untreated advanced non–small-cell lung cancer.\" Ann Oncol. 2009;20(3):419-426.\n        \u003C/li>\n        \u003Cli>\n          Hauschild A, et al. \"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 trial.\" Lancet. 2012;380(9839):358-365.\n        \u003C/li>\n        \u003Cli>\n          Hurwitz H, et al. \"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.\" N Engl J Med. 2004;350(23):2335-2342.\n        \u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立命名，避免全局冲突 */\n.practical-drug-guide {\n  font-family: \"Microsoft YaHei\", Arial, Helvetica, sans-serif;\n  color: #222;\n  background: #f9f9fa;\n  border-radius: 18px;\n  margin: 30px auto 36px auto;\n  max-width: 820px;\n  padding: 32px 26px 32px 26px;\n  box-shadow: 0 4px 28px rgba(40, 50, 90, 0.13);\n}\n\n.practical-drug-guide__main-title {\n  font-size: 2.2em;\n  font-weight: bold;\n  text-align: center;\n  line-height: 1.32;\n  letter-spacing:1.5px;\n  color: #227396;\n  margin-bottom: 16px;\n}\n\n.practical-drug-guide__lead {\n  font-size: 1.08em;\n  color: #48616f;\n  margin: 24px 0 32px 0;\n  text-align: justify;\n  background: #dff3f8;\n  padding: 18px 22px;\n  border-radius: 12px;\n}\n\n.practical-drug-guide__section {\n  margin-bottom: 34px;\n  background: #fff;\n  border-radius: 10px;\n  box-shadow: 0 2px 12px rgba(120,140,160,.07);\n  padding-bottom: 2px;\n}\n\n.practical-drug-guide__section-header {\n  border-radius: 10px 10px 0 0;\n  padding: 14px 28px 12px 22px;\n  font-size: 1.18em;\n  letter-spacing: 0.8px;\n  font-weight: 700;\n  position: relative;\n}\n\n.practical-drug-guide__bg1 {background:linear-gradient(90deg,#e3f7ff 30%,#eaf5fb 100%);}\n.practical-drug-guide__bg2 {background:linear-gradient(90deg,#e0ebff 0%,#f6faff 100%);}\n.practical-drug-guide__bg3 {background:linear-gradient(90deg,#effaf2 3%,#eaf3eb 100%);}\n.practical-drug-guide__bg4 {background:linear-gradient(90deg,#fff6e3 2%,#fdf7e8 100%);}\n.practical-drug-guide__bg5 {background:linear-gradient(90deg,#eaecf7 5%, #f7f8fa 100%);}\n.practical-drug-guide__bg6 {background:linear-gradient(90deg, #fff0f0 2%, #fcf8f7 100%);}\n.practical-drug-guide__bg7 {background:linear-gradient(90deg,#f6fbe9 7%,#fefb 100%);}\n.practical-drug-guide__bg8 {background:linear-gradient(90deg,#f0f8ff 5%,#f6fafd 100%);}\n.practical-drug-guide__bg9 {background:linear-gradient(90deg, #eef7f4 3%, #f7fbff 100%);}\n.practical-drug-guide__bg10 {background: linear-gradient(90deg, #e9e1fa 0%, #f9f8fc 100%);}\n\n.practical-drug-guide__section-header h2 {\n  margin: 0;\n  color: #277da1;\n  font-size: 1.16em;\n  display: flex;\n  gap: 4px;\n  align-items: center;\n}\n\n.practical-drug-guide__section-content {\n  font-size: 1.06em;\n  color: #22496b;\n  line-height: 1.8;\n  padding: 23px 28px 9px 24px;\n}\n\n.practical-drug-guide__section-content ul {\n  padding-left: 18px;\n  margin-bottom: 8px;\n}\n\n.practical-drug-guide__section-content li {\n  margin-bottom: 8px;\n  line-height:1.74;\n}\n\n.practical-drug-guide__section-content p {\n  margin: 13px 0 0px 0;\n  color: #427e9d;\n}\n\n.practical-drug-guide__refs ol {\n  margin-left: 16px;\n  color: #3b5d77;\n  font-size: 1.02em;\n  line-height: 1.76;\n  padding: 3px 0 11px 2px;\n}\n\n.practical-drug-guide__conclusion {\n  margin: 32px 0 18px 0;\n  font-size: 1.14em;\n  color: #46505b;\n  background: #f0f5fa;\n  border-left: 5px solid #52b0db;\n  border-radius: 4px;\n  padding: 22px 30px 18px 25px;\n  line-height: 1.82;\n}\n\n@media (max-width: 600px) {\n  .practical-drug-guide {\n    padding: 12px 3% 18px 3%;\n    border-radius: 12px;\n  }\n  .practical-drug-guide__main-title {font-size:1.28em;}\n  .practical-drug-guide__lead,\n  .practical-drug-guide__conclusion {\n    padding: 13px 8px;\n    font-size: 0.95em;\n  }\n  .practical-drug-guide__section-content {\n    font-size:0.94em;\n    padding:12px 0 7px 13px;\n  }\n  .practical-drug-guide__section-header {\n    font-size: 0.99em;\n    padding: 11px 3% 8px 3%;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"practical-drug-guide\">\n  \u003C!-- 标题 -->\n  \u003Ch1 id=\"material_title\" class=\"practical-drug-gui",441,"2025-12-09 01:24:32","肺腺癌,老年患者,抗肿瘤药,靶向药,用药安全,不良反应,药物相互作用","本文深入解析四期肺腺癌老年患者的用药细节，包括抗肿瘤药、靶向药与辅助药的使用注意事项，帮助患者及家属提升安全用药意识。","2025-12-15 14:27:48",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]